Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of marstacimab prophylaxis in severe hemophilia A or moderately severe to severe hemophilia B
2022-500470-33-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, open-label, single-arm trial of marstacimab in hemophilia A and hemophilia B (HB), sponsored by Pfizer. Primary endpoints: Adverse events and serious adverse events, Thrombotic events and 7 more. Planned start Nov 2022; status: authorised.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2022-500470-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500470-33-00.